This score has yet to be evaluated in patients with synchronous disease, but as disease-free interval is no longer a component of the modified risk score, there is a relative indication in favour of establishing KRAS mutation status from the primary tumour in situations where this is feasible. This evidence concerns the gene KRAS and neoplasm.